Synthesis and evaluation of amide and thioureas derivatives as Carbonic Anhydrase (CAs) inhibitors

Zahid Hussain^{*1}, Abid Mahmood², Qasim Shah², Aqeel Imran², Ehsan Ullah Mughal³, Wajiha Khan⁴, Ayesha Baig⁴, Jamshed Iqbal^{*2}, Amara Mumtaz^{*1}

¹Department of Chemistry, COMSATS University Islamabad, Abbottabad Campus, Abbottabad 22060, Pakistan.

²Center for Advance Drug Research, COMSATS University Islamabad, Abbottabad Campus, Abbottabad

22060, Pakistan.

³Department of Chemistry University of Gujrat, Gujrat 50700, Pakistan.

⁴Department of Biotechnology, COMSATS University Islamabad, Abbottabad Campus, Abbottabad 22060, Pakistan.

List of Figure

Figure S1: ¹ H NMR of compound 20	3
Figure S2: ¹³ C NMR of compound 20	3
Figure S3: ¹ H NMR of compound 22	4
Figure S4: ¹³ C NMR of compound 22	4
Figure S5: ¹ H NMR of compound 23	5
Figure S6: ¹³ C NMR of compound 23	5
Figure S7: ¹ H NMR of compound 21	6
Figure S8: ¹³ C NMR of compound 21	6
Figure S9: ¹ H NMR of compound 18	7
Figure S10: ¹³ C NMR of compound 18	7
Figure S11: ¹ H NMR of compound 17	8
Figure S12: ¹³ C NMR of compound 17	8
Figure S13: ¹ H NMR of compound 12	9
Figure S14: ¹³ C NMR of compound 12	9
Figure S15: ¹ H NMR of compound 09	10
Figure S16: ¹³ C NMR of compound 09	10
Figure S17: ¹ H NMR of compound 24	11
Figure S18: ¹³ C NMR of compound 24	11
Figure S19: ¹ H NMR of compound 26	12
Figure S20: ¹³ C NMR of compound 26	12
Figure S21: ¹ H NMR of compound 10	13
Figure S22: ¹³ C NMR of compound 10	13
Figure S23: ¹ H NMR of compound 11	14
Figure S24: ¹³ C NMR of compound 11	14

Figure S25: ¹ H NMR of compound 14	15
Figure S26: ¹³ C NMR of compound 14	15
Figure S27: ¹ H NMR of compound 15	16
Figure S28: ¹³ C NMR of compound 15	16
Figure S29: ¹ H NMR of compound 25	17
Figure S30: ¹³ C NMR of compound 25	17
Figure S31: ¹ H NMR of compound 13	18
Figure S32: ¹³ C NMR of compound 13	18
Figure S33: IR graph of Compound 20	19
Figure S34: IR graph of Compound 23	19
Figure S35: IR graph of Compound 21	20
Figure S36: IR graph of Compound 18	20
Figure S37: IR graph of Compound 17	21
Figure S38: IR graph of Compound 12	21
Figure S39: IR graph of Compound 20	22
Figure S40: IR graph of Compound 24	22
Figure S41: IR graph of Compound 26	23
Figure S42: IR graph of Compound 10	23
Figure S43: IR graph of Compound 11	24
Figure S44: IR graph of Compound 14	24
Figure S45: IR graph of Compound 15	25
Figure S46: IR graph of Compound 25	25
Figure S47: IR graph of Compound 20	26
Figure S48: HPLC chromatogram of compound 20 and 23	27
Figure S49: Analysis of cell viability/cytotoxicity using HEK-293 cells treated with compounds 1-17 at final concentration	n (100 µM).
$Statistics \ indicating \ significant \ values \ *p < 0.05, \ **p < 0.01, \ ***p < 0.001 \ vs. \ untreated \ group. \ Cisplatin \ (100 \ \mu M) \ is \ used \ where \ $	as a positive
control	34
Figure S50: 2D interaction of Compound 09	35
Figure S51: 2D interaction and geometrical graph of compound 11	35
Figure S52: 2D interaction Compound 12	36
Figure S53: 2D interaction Compound 18	

List of Tables

Table S1: IC ₅₀ values and Graphs of hCA II	29
Table S2: IC ₅₀ vales and Graphs of hCA IX	32
Table S3: IC ₅₀ vales and Graphs of hCA XII	

1.1 Proton NMR, ¹³C Spectra of the synthesized compounds



Figure S2: ¹³C NMR of compound 20





Figure S4: ¹³C NMR of compound 22







Figure S6: ¹³C NMR of compound 23



Figure S7: ¹H NMR of compound 21



Figure S8: ¹³C NMR of compound 21



Figure S9: ¹H NMR of compound 18



Figure S10: ¹³C NMR of compound 18



Figure S11: ¹H NMR of compound 17



Figure S12: ¹³C NMR of compound 17









Figure S14: ¹³C NMR of compound 12







Figure S16: ¹³C NMR of compound 09





Figure S17: ¹H NMR of compound 24



Figure S18: ¹³C NMR of compound 24



Figure S19: ¹H NMR of compound 26





Compound 10



Figure S21: ¹H NMR of compound 10



Figure S22: ¹³C NMR of compound 10



Figure S23: ¹H NMR of compound 11



Figure S24: ¹³C NMR of compound 11



Figure S25: ¹H NMR of compound 14



Figure S26: ¹³C NMR of compound 14



Figure S27: ¹H NMR of compound 15



Figure S28: ¹³C NMR of compound 15



Figure S30: ¹³C NMR of compound 25

Figure S32: ¹³C NMR of compound 13

2 Supporting IR spectra of the synthesized compounds

Figure S33: IR graph of Compound 20

Figure S34: IR graph of Compound 23

Figure S36: IR graph of Compound 18

Figure S38: IR graph of Compound 12

Figure S40: IR graph of Compound 24

Figure S42: IR graph of Compound 10

Figure S43: IR graph of Compound 11

Figure S44: IR graph of Compound 14

Figure S46: IR graph of Compound 25

Figure S47: IR graph of Compound 20

HPLC Chromatogram

Figure S48: HPLC chromatogram of compound 20 and 23

3 *In-vitro* studies of the synthesized compounds and their IC_{50} values.

h-Carbonic Anhydrase-II (hCA-II)			
Compounds	Structure	Graph	IC50
09	Molecular Weight: 336.36	0.32 0.28 0.26 0.24 0.22 5 4 .3 .2 .1 0 conc.(mM)	0.18 ± 0.05
10	Molecular Weight: 304.36	1.4 1.2 g g 1.0 0.8 0.6 -5 -5 -4 conc.(mM)	0.93 ± 0.05
11	H ₂ NO ₂ S CI Nolecular Weight: 244.66	20 1.5 9 1.0 0.5 0.5 0.5 -4 -3 -2 -1 0 conc.(mM)	1.18 ± 0.14
14	NO ₂ NO ₂ NO ₂ Cl Molecular Weight: 304.73	0.25 0.20- 0.15- 0.10- 0.05- 0.00- -5 4 -3 -2 -1 0 conc.(mM)	6.49 ± 0.63
15	H Molecular Weight: 372.19	0.22 9 0.20- 0.18- 0.16- 5 4 -3 -2 -1 0 conc.(mM)	1.93 ± 0.15

Table S1: IC $_{\rm 50}$ values and Graphs of hCA II

Human Carbonic Anhydrase IX (hCA-IX)			
Compounds	STRUCTURE	GRAPH	IC ₅₀
10	H ₂ NO ₂ S CI N H Molecular Weight: 244.66	0.20 0.19 0.18 0.17- 0.16 	14.58 ± 1.07
11	NO ₂ NO ₂ N H Cl Molecular Weight: 304.73	0.20 0.19 2 0.18 0.17 0.16 -5 -5 -5 -5 -5 -5 -5 -5 -5 -5 -1	0.17 ± 0.05
13	Molecular Weight: 269.30	0.22 0.20 § 0.18 0.16 0.14 -5 -4 -3 -2 -1 0 conc.(mM)	10.36 ± 1.45
17	$H_2NO_2S \xrightarrow{V} SO_2NH_2$ $CI \xrightarrow{V} H \xrightarrow{O} O$ $S \xrightarrow{V} H \xrightarrow{O} O$ Molecular Weight: 508.96	0.20 0.18 0.16 0.14 0.12 0.10 5 4 3 2 1 0 conc.(mM)	1.71 ± 0.65
18	HO HO N N H	0.18- 0.16- 0.14- 5-4-3-2-1-0 conc.(mM)	0.21± 0.09
19	O_2N H Br S O	0.22 0.20 8 0.18 0.16 0.14 0.14 0.14 0.14 0.16	1.01 ± 0.05
22	O O O H H H Cl Molecular Weight: 395.81	0.20 0.15 0.16 0.10 -5 -4 -3 -2 -1 0 conc.(mM)	4.93 ± 1.83

Table S2: IC $_{50}$ vales and Graphs of hCA IX

24	OH H H H H H H H H H H H H H H H H H H	0.24 0.22- 0.20- 0.18- 0.16- 0.14- 5 4 3 -2 -1 0 conc.(mM)	1.25 ± 0.02
25	HO HO N H H H H H H H H H H H H H H H H	0.25 0.20- 2 0.15- -5 4 -3 -2 -1 0 conc.(mM)	9.76 ± 1.03
26	HO CI N H H H H H H H H H H H H H H H H H H	0.24 0.23 # 0.22- 0.21- 0.20- 0.21- 0.20- 0.21- 0.20- 0.21- 0.20- 0.21- 0.20- 0.21- 0.20- 0.21- 0.20- 0.21- 0.	1.28 ± 0.09

h-Carbonic Anhydrase-XII (hCA-XII)			
Compounds	STRUCTURE	GRAPH	IC ₅₀
Compound 10	H ₂ N ^{-S} O H	0.34 0.32 0.32 0.28 0.28 0.26 0.28 0.26 0.28 0.28 0.28 0.28 0.28 0.28 0.28 0.28 0.28 0.30 0.28 0.30 0.28 0.30 0.28 0.30 0.28 0.30 0.28 0.30 0.28 0.30 0.38	9.17 ± 0.85
Compound 11	H ₂ NO ₂ S CI N H	0.30 Generation Compound 11 Generation Compound 11	2.99 ± 0.32
Compound 12	H ₂ NO ₂ S Cl	0.14 0.13 0.12 0.11 0.10 5 4 Compound 12 0.12 0.11 0.10 5 5 4 Compound 12	0.58 ± 0.06
Compound 14		0.5 0.4 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3	0.95 ± 0.08
Compound 15	O N H F F	0.16 0.15 0.14 0.13 0.12 0.11 0.12 0.11 0.12 0.11 0.12 0.11 0.12 0.11 0.13 0.12 0.12 0.14 0.13 0.14 0.15 0.15 0.14 0.15 0.5 0.5 0.5 0.5 0.5 0.5 0.5 0.	1.05 ± 0.11
Compound 18	HO HO N H H H H H H H H H H H H H H H H	0.12 0.11 0.10 0.00 0.00 0.00 0.00 0.00	1.68 ± 0.15
Compound 22	$ \begin{array}{c} \begin{array}{c} \begin{array}{c} \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \begin{array}{c} \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} \\ \end{array} $	0.13 0.12 9 0.11 0.10 0.10 0.10 0.10 0.10 0.10 0.	4.29 ± 0.24

Table S3: IC ₅₀	vales and	Graphs	of hCA	XII
----------------------------	-----------	--------	--------	-----

4 Cell Viability assay

Figure S49: Analysis of cell viability/cytotoxicity using HEK-293 cells treated with compounds 1 –17 at final concentration (100 μ M). Statistics indicating significant values *p < 0.05, **p < 0.01, ***p < 0.001 vs. untreated group. Cisplatin (100 μ M) is used as a positive control.

5 Docking interaction of the synthesized compounds

2D interaction of the compounds 09 and 11

Figure S50: 2D interaction of Compound 09

Figure S51: 2D interaction and geometrical graph of compound 11

Interaction of compounds 12 and 18 against hCA XII

Figure S52: 2D interaction Compound 12

